Ethics statement
HOOKWORM
The Ugandan Vector Control Division Research Ethics committee (VCDREC; reference number: UG-REC-018/VCDREC104), Uganda National Council for Science and Technology (UNCST; reference number: HS1411ES), National Drug Authority (NDA; reference number: CTC 0202/2022) and the London School of Hygiene and Tropical Medicine ethics committee (LSHTM ethic reference:25818) approved the trial. The trial is registered in the Pan African Clinical Trial Registry (registry number: PACTR202202738940158). The authors designed, recorded and reported this trial according to GCP standards. In addition, a designated monitoring expert approved by Ugandan NDA monitored this trial to ensure that GCP standards were met. Written assent forms were obtained from all participants, along with written consent forms from their guardians.This trial was embedded within the framework of the Mayuge NTD Elimination (MANE) project funded by Korean International Cooperation Agency (KOICA). A prevalence survey was undertaken in January-February 2022 to evaluate the impact of the MANE project implemented between 2019 and 2021. Children who were identified as hookworm positive in the 2022 prevalence survey were invited to take part in the trial. We followed the CONSORT checklist to report this trial (